# To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Study · id `cardio:ct-nct06901505` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06901505](<https://clinicaltrials.gov/study/NCT06901505>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06901505

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 353 participants.

## Technical summary

Registry record NCT06901505. Randomized; no masking; primary purpose treatment. Start 2025-07-24 (actual); primary completion 2026-08-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 353 participants (enrolled count; ClinicalTrials.gov record NCT06901505, source copy `cardio:ctgov-nct06901505-2026-11-16`, retrieved 2026-11-18)
- Started: 2025-07-24 (actual) (ClinicalTrials.gov record NCT06901505, source copy `cardio:ctgov-nct06901505-2026-11-16`, retrieved 2026-11-18)
- Primary completion: 2026-08-12 (actual) (ClinicalTrials.gov record NCT06901505, source copy `cardio:ctgov-nct06901505-2026-11-16`, retrieved 2026-11-18)
- Completion: 2026-08-12 (actual) (ClinicalTrials.gov record NCT06901505, source copy `cardio:ctgov-nct06901505-2026-11-16`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT06901505, source copy `cardio:ctgov-nct06901505-2026-11-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06901505-2026-11-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
- Condition: Anemia of Chronic Kidney Disease
- Intervention (Drug): Erythropoiesis-Stimulating Agent (ESA)
- Intervention (Drug): Vadadustat
- Lead sponsor: Akebia Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Akebia Therapeutics (`cardio:org-akebia-therapeutics`)

## Provenance

Content hash: 1833a7181c4e14c5269d6ef0696772437cbcc6b772faadba805e237cf2f617e4
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
